LEXEO THERAPEUTICS INC (LXEO)
Sector: Health Care
2026 Annual Meeting Analysis
LEXEO THERAPEUTICS INC · Meeting: June 25, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
AGAINST
Director Elections
Election of Class III Directors
Townsend has served as CEO and director since 2020, giving him meaningful tenure, but as a biotech executive director he is subject to the TSR trigger; however, LXEO went public in November 2023, so 3-year price return data covering his full tenure as a public-company director is limited, and the stock's 1-year return of +5% versus XBI's +78.9% reflects a significant gap but insufficient confirmed 3-year data to fire the trigger conclusively — no overboarding, no attendance issues, and strong industry qualifications support a FOR vote.
Cholmondeley has served since November 2021 and chairs the audit committee; she is a former CPA and former CFO of Independence Blue Cross, making her clearly qualified as the audit committee financial expert, and she holds three public board seats (LXEO, Bank OZK, Terex) which is within the four-seat limit, with no attendance issues disclosed.
Cooperstone joined the board in August 2023, which is less than 36 months ago and her tenure as a public-company director at LXEO began only shortly before the IPO in November 2023, so she falls within the window where the TSR trigger is mitigated by limited tenure overlap; she brings deep biopharma clinical development expertise from Pfizer Rare Disease and holds two board seats, well within policy limits.
All three Class III director nominees — Townsend, Cholmondeley, and Cooperstone — pass policy screens on overboarding, attendance, qualifications, and independence. The TSR underperformance concern (LXEO +5% vs. XBI +78.9% over one year) is noted but the company only went public in November 2023, making a full 3-year TSR comparison unavailable; the trigger cannot be confirmed to fire without the required data window. No familial relationships or independence concerns were identified. Vote FOR all three.
Say on Pay
✓ FORCEO
R. Nolan Townsend
Total Comp
$3,650,940
Prior Support
N/A
This is LXEO's first say-on-pay vote as a public company (IPO was November 2023), so there is no prior-year vote history to evaluate. The CEO's total reported compensation of $3,650,940 for 2025 is within a reasonable range for a CEO of a clinical-stage biotech with a ~$369M market cap, and the pay mix is heavily weighted toward variable compensation — stock awards ($1,493,488) and stock option awards ($1,165,982) together represent approximately 73% of total compensation, well above the 50-60% threshold the policy requires. While LXEO's stock has significantly underperformed the XBI — SPDR S&P Biotech ETF benchmark over the past year (+5% vs. +78.9%), the company is pre-revenue and clinical-stage, the equity grants were made at prices that are now underwater for most 2024-2025 grants (exercise prices of $7.33–$14.48 vs. current price of $4.70), meaning executives have not realized gains inconsistent with shareholder experience, and performance stock awards with clinical milestone conditions were included in the program, providing genuine performance linkage.
Auditor Ratification
✗ AGAINSTAuditor
KPMG LLP
Tenure
N/A
Audit Fees
$660,000
Non-Audit Fees
$763,480
The fees paid to KPMG for services beyond the core audit ($763,480 in audit-related fees, primarily consisting of consents and comfort letters for securities offerings) exceeded the core audit fees ($660,000), producing a non-audit-to-audit ratio of approximately 116% — well above the 50% threshold that triggers a No vote under our policy. While the audit-related fees appear connected to capital-raising activity rather than unrelated consulting work, the policy treats audit-related fees as non-audit for ratio purposes, and the ratio is too high to support ratification. KPMG is a Big 4 firm appropriate for LXEO's size, and no restatements or tenure concerns were identified, but the fee ratio concern is the sole but clear basis for an AGAINST vote.
Actual Vote Results
Meeting held June 25, 2026
Director Elections
| Nominee | % FOR | Votes For | Withheld / Against | Result |
|---|---|---|---|---|
| R. Nolan Townsend | 98.6% | 64.7M | 895,808 | ✓ Elected |
| Paula HJ Cholmondeley | 98.5% | 64.7M | 974,575 | ✓ Elected |
| Brenda Cooperstone, M.D. | 74.3% | 48.8M | 16.8M | ✓ Elected |
Auditor Ratification
For 75.5M · Against 55,579 · Abstain 30,099
Overall Assessment
The 2026 LXEO annual meeting features three proposals: a director election, auditor ratification, and an implicit say-on-pay review (compensation is disclosed but no separate say-on-pay proposal appears on the ballot this year as this is early in the company's public life). We vote FOR all three director nominees based on relevant qualifications and limited public-company tenure overlap with the underperformance period, FOR on executive compensation given a variable-pay-heavy structure and underwater equity awards that align executive and shareholder experience, but AGAINST KPMG ratification solely because audit-related fees for securities offerings caused the non-audit fee ratio to exceed 116% of core audit fees, breaching the 50% independence threshold.